S6:E4 – Oncology Morning Commute: Targeting HER2, HER3, and TROP2 in NSCLC

Hematology / Oncology @Point of Care Podcasts

English - February 28, 2022 21:00 - 26 minutes - 36.9 MB
Medicine Health & Fitness checkpointinhibitors cmece endometrialcancer immunotherapy Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: S6:E3 – Oncology Morning Commute: ADCs for NSCLC—Ready for Prime Time?

Next Episode: S6:E5 – Oncology Morning Commute: Targeted Therapies for Gastroesophageal and Colorectal Cancers

Our faculty continue their discussion on antibody-drug conjugates and look at some of the promising trials in NSCLC for these promising therapies.

Visit www.morningcommutepodcast.com/solidtumors4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.